Fact CheckerSign in

NCT05826054CompletedPhase 1

Montbretin Clinical Trial in Healthy Volunteers and Type 2 Diabetics

Phase 1 Dose Escalating Study for Montbretin A

Source: ClinicalTrials.gov · Last updated 2 Sept 2026

Brief summary (registry, in English)

The goal of this clinical trial is to test the investigational product, Montbretin A (MbA) in either individuals with type 2 diabetes (T2D) or healthy participants. The main questions it aims to answer are: * Safety of MbA * Whether MbA has less side effects in comparison to other medications used to treat T2D Participants will: * Be given MbA at increasing amounts (10 mg to 300 mg) over a two-week treatment period, along with standardized meal; * Undergo testing, including blood draws, blood sugar checks, electrocardiogram (ECG) and questionnaires.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
15 (actual)
First submitted
11 Apr 2023
Start date
1 Dec 2023
Primary completion date
25 Nov 2025
Lead sponsor
Robert Petrella
NCT number
NCT05826054

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 15
  • From 1 Dec 2023 to the primary completion date, 25 Nov 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Currently on medication, except vitamins and/or birth control
  • Travelled to a foreign country less than four (4) weeks prior to study entry;
  • Surgery less than four (4) weeks a prior to study entry;
  • Planning to participate in other investigational drugs while participating in the study;

Other illness

  • Current or a history of impairment of gastro-intestinal function, including but not limited to inflammatory bowel disease, colonic ulceration, and/or partial intestinal obstruction
  • Known allergy to study medication or its components (non-medicinal ingredients); and
  • A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits

Other

  • Currently in poor health, as determined by the study doctor
  • Not eating three regular meals a day
  • Pregnant or lactating women;

Who the study is looking for

  • Male or female, age ≤ 65 years; ≥19 years;
  • Have diagnosed type-2 diabetes mellitus with HbA1C between 6.5% to 11% that is currently managed by diet and no other medications or healthy volunteers defined as not having diagnosis of type-2 diabetes mellitus.
  • Have routine and normal dietary habits that include three meals a day;
  • Normal hematological parameters as determined through an in-person screening blood draw including HbA1C \>4.0% in healthy volunteers.
  • Use of an effective barrier method of birth control throughout the study, surgical sterility, or menopausal for at least 2 years;
  • In the study team's opinion, capable of understanding the visit schedule requirement and study medication dosing requirements.
  • Be able to avoid all supplements that affect blood sugar for the duration of the study eg. chromium, bitter melon, thiamine, berberine, alpha-lipoic acid, devil's claw, horse chestnut, fenugreek, ginseng, psyllium, cinnamon, garlic and panax.

Age in the registry: 19 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
VCHRI Clinical Research Unit
Coordinator of this site? Confirm its status
VancouverCanadaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.